G Jerums

Author PubWeight™ 102.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995 4.06
2 Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001 2.20
3 A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997 1.77
4 Reduced bone mass in daughters of women with osteoporosis. N Engl J Med 1989 1.70
5 Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991 1.58
6 Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia 1989 1.57
7 Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 2003 1.55
8 The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995 1.46
9 Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia 2006 1.42
10 Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 1994 1.40
11 Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes. Med J Aust 2001 1.39
12 Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats. Kidney Int 1998 1.36
13 Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies. Intern Med J 2002 1.35
14 A comparison of guanacline with methyldopa in the treatment of hypertension. Med J Aust 1968 1.21
15 Methyldopa and haemolytic anaemia. Med J Aust 1967 1.13
16 Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest 1997 1.12
17 Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 2000 1.09
18 The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabet Med 2007 1.08
19 Effect of thyroid status on ouabain binding to the human lymphocyte. J Clin Endocrinol Metab 1982 1.06
20 Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000 1.03
21 Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000 1.03
22 Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate. Diabetologia 2005 0.97
23 Clinical, biochemical and histological observations on the effect of porcine calcitonin in Paget's disease of bone. Aust N Z J Med 1977 0.97
24 Patterns of glycaemic control in Australian primary care (NEFRON 8). Intern Med J 2008 0.97
25 Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001 0.97
26 Microalbuminuria: prognostic and therapeutic implications in diabetes mellitus. Diabet Med 1994 0.96
27 Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. Diabet Med 1996 0.96
28 Increased epidermal growth factor in experimental diabetes related kidney growth in rats. Diabetologia 1997 0.95
29 Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. Atherosclerosis 1995 0.94
30 Plasma renin levels and vascular complications in hypertension. Br Med J 1973 0.94
31 Effects of genetic hypertension on diabetic nephropathy in the rat--functional and structural characteristics. J Hypertens 1988 0.94
32 Inflammation, hepatic enzymes and resistance training in individuals with metabolic risk factors. Diabet Med 2009 0.92
33 Early nephropathy predicts vision-threatening retinal disease in patients with type I diabetes mellitus. J Am Soc Nephrol 1998 0.92
34 Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 1998 0.91
35 Salt supplementation blunts the blood pressure response to telmisartan with or without hydrochlorothiazide in hypertensive patients with type 2 diabetes. Diabetologia 2010 0.91
36 The effect of acute exercise on undercarboxylated osteocalcin in obese men. Osteoporos Int 2010 0.91
37 The CARI guidelines. Assessment of kidney function in type 2 diabetes. Nephrology (Carlton) 2010 0.90
38 Alterations in renal degradation of albumin in early experimental diabetes in the rat: a new factor in the mechanism of albuminuria. Clin Sci (Lond) 1998 0.90
39 Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 1997 0.89
40 Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes. Diabetes 1997 0.89
41 Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int 1999 0.89
42 Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD). J Clin Endocrinol Metab 1992 0.89
43 Differential renal protein clearance in diabetes. Diabetes 1973 0.88
44 Fractional clearance of albumin is influenced by its degradation during renal passage. Clin Sci (Lond) 1997 0.88
45 Diabetic vascular complications. Clin Exp Pharmacol Physiol 1997 0.88
46 Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. Am J Hypertens 1988 0.87
47 Functional erythropoietin deficiency in patients with Type 2 diabetes and anaemia. Diabet Med 2006 0.87
48 Progression of proteinuria in type 1 and type 2 diabetes. Diabet Med 1988 0.87
49 Pathogenesis and intervention strategies in diabetic retinopathy. Clin Experiment Ophthalmol 2001 0.86
50 Renal sodium handling and responsiveness of plasma renin levels in hypertension. Clin Sci 1969 0.86
51 Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001 0.86
52 Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 1996 0.86
53 Anaphylaxis to suxamethonium. A case report. Br J Anaesth 1967 0.86
54 Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. Diabetes 1990 0.85
55 Metabolism and blood levels following infusion of a radioactive analog of angiotensin. Am J Physiol 1968 0.85
56 Glomerular filtration rate in streptozocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy. Diabetes 1990 0.85
57 Albuminuric and non-albuminuric pathways to renal impairment in diabetes. Minerva Endocrinol 2005 0.85
58 Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 1998 0.85
59 Phaeochromocytoma in the elderly: a poorly recognised entity? Br Med J (Clin Res Ed) 1986 0.85
60 Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye. Connect Tissue Res 1999 0.84
61 Effect of early menopause on bone mass in normal women and patients with osteoporosis. Am J Med 1988 0.84
62 Proteolysis of insulin-like growth factor-binding protein-3 is increased in urine from patients with diabetic nephropathy. J Clin Endocrinol Metab 2000 0.83
63 The development of Cushing's syndrome from a previously silent pituitary tumour. Aust N Z J Med 1987 0.83
64 Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer. Med J Aust 1981 0.83
65 The CARI guidelines. Prevention and management of chronic kidney disease in type 2 diabetes. Nephrology (Carlton) 2010 0.82
66 Effect of puberty on initial kidney growth and rise in kidney IGF-I in diabetic rats. Diabetes 1990 0.81
67 Performance of formulas for estimating glomerular filtration rate in Indigenous Australians with and without Type 2 diabetes: the eGFR Study. Diabet Med 2014 0.81
68 Extracellular matrix and its interactions in the diabetic kidney: a molecular biological approach. J Diabetes Complications 1996 0.81
69 High sodium and low potassium intake in patients with Type 2 diabetes. Diabet Med 2010 0.81
70 Serum total renin is increased before microalbuminuria in diabetes. Kidney Int 1996 0.81
71 Increased bone mineral density in Aboriginal and Torres Strait Islander Australians: impact of body composition differences. Bone 2012 0.81
72 Low serum C4 concentrations and microangiopathy in type I and type II diabetes. Br Med J (Clin Res Ed) 1986 0.80
73 Interlaboratory variation of GHb assays in Victoria, Australia. Diabetes Care 1996 0.80
74 A comparison of the plasma disappearance of iohexol and 99mTc-DTPA for the measurement of glomerular filtration rate (GFR) in diabetes. Aust N Z J Med 1999 0.80
75 A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia 1999 0.80
76 Prediction of persistent microalbuminuria in patients with diabetes mellitus. J Diabetes Complications 1993 0.80
77 Long-term use of intranasal insulin in insulin-dependent diabetic patients. Diabetes Care 1988 0.80
78 Urinary transforming growth factor-beta in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology. Nephrol Dial Transplant 2001 0.80
79 Spectrum of proteinuria in type I and type II diabetes. Diabetes Care 1987 0.80
80 Disparate effects of castration on renal structure and function in the streptozotocin diabetic rat. Diabetes Res 1994 0.79
81 The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy. Diabetes 1993 0.79
82 SPARC gene expression is reduced in early diabetes-related kidney growth. Kidney Int 1995 0.79
83 Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. Clin Sci (Lond) 2001 0.78
84 Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. Kidney Int 1992 0.78
85 Effect of glycation of albumin on its renal clearance in normal and diabetic rats. Kidney Int 1988 0.78
86 Effects of intranasal insulin in non-obese type II diabetics. Diabetes Res Clin Pract 1987 0.77
87 Estimating dual-energy X-ray absorptiometry-derived total body skeletal muscle mass using single-slice abdominal magnetic resonance imaging in obese subjects with and without diabetes: a pilot study. Eur J Clin Nutr 2012 0.77
88 Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat. Invest Ophthalmol Vis Sci 1996 0.77
89 The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes. Nephrology (Carlton) 2010 0.77
90 Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats. Diabetologia 2001 0.77
91 Measurement of iohexol by capillary electrophoresis: minimizing practical problems encountered. Ann Clin Biochem 2000 0.77
92 Sodium balance, plasma renin, and aldosterone in hypertension. Circ Res 1970 0.77
93 Detection of microalbuminuria in diabetic patients by urinary dipstick. Diabetes Res Clin Pract 1997 0.77
94 The effects of dietary cholesterol on experimental diabetic nephropathy. Diabetes Res 1993 0.77
95 Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk 1994 0.77
96 Oxygen (O2) kinetics during early recovery from peak exercise in patients with Type 2 diabetes. Diabet Med 2011 0.77
97 Immuno-unreactive albumin excretion increases in streptozotocin diabetic rats. Am J Kidney Dis 2001 0.77
98 Day-night blood pressure variation in normotensive, normoalbuminuric type I diabetic subjects. Dippers and non-dippers. Diabetes Care 1994 0.77
99 Diabetes-related renal growth and IGF-I accumulation in castrated rats. Diabetes Res Clin Pract 1991 0.76
100 Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study. Diabetes Res Clin Pract 1987 0.76
101 The cyclic AMP response to glucagon. Comparison of tissue and plasma cyclic AMP levels in the rabbit. Diabetes 1977 0.76
102 Carbimazole-induced agranulocytosis: does antineutrophil cytoplasmic antibody have a role? Intern Med J 2010 0.76
103 Focal induction of IGF binding proteins in proximal tubules of diabetic rat kidney. Diabetes 1992 0.76
104 Kidney insulin-like growth factor-I mRNA levels are increased in postpubertal diabetic rats. J Endocrinol 1991 0.76
105 Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism. J Clin Endocrinol Metab 1991 0.76
106 Primary prevention of stroke. N Engl J Med 1996 0.75
107 Angiotensin-converting enzyme (ACE) gene polymorphism in type II diabetic patients with increased albumin excretion rate. J Diabetes Complications 1996 0.75
108 Hyperlipidaemia increases albuminuria in hypertensive and normotensive rats. Clin Exp Pharmacol Physiol 1990 0.75
109 Cyclic AMP and gastric acid secretion in the dog. Aust N Z J Surg 1982 0.75
110 The biguanides: action and clinical indications. Aust Fam Physician 1976 0.75
111 Relationship between ambulatory blood pressure and albuminuria in normal subjects. Am J Hypertens 1991 0.75
112 The treatment of hirsutism: experience with cyproterone acetate and spironolactone. Australas J Dermatol 1985 0.75
113 Ramipril reduces albuminuria in diabetic rats fed a high protein diet. Clin Exp Pharmacol Physiol 1989 0.75
114 Nuclear scanning in the diagnosis and localization of parathyroid adenomas. Med J Aust 1986 0.75
115 Effects of insulin therapy and glycemic control on distribution of HDL alpha and pre-beta subfractions in non insulin-dependent diabetic subjects. Nutr Metab Cardiovasc Dis 1999 0.75
116 Diabetic dyslipidaemia. Australian Diabetes Society position statement. Med J Aust 1995 0.75
117 Dissociation of blood pressure and albuminuria in normal subjects infused with angiotensin II and noradrenaline. Clin Exp Pharmacol Physiol 1993 0.75
118 Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease. J Clin Endocrinol Metab 1996 0.75
119 Plasma angiotensinase activity in relation to the breakdown of phenylthiocarbamyl-angiotensin II amide in hypertensive and normotensive patients. Cardiovasc Res 1968 0.75
120 An evaluation of secondary failure to tolbutamide therapy. Aust N Z J Med 1974 0.75
121 Angiotensin converting enzyme inhibitors and diabetic renal disease. ACE inhibitors may prevent progression from incipient to clinical nephropathy. Med J Aust 1994 0.75
122 The effect of modifying the combination of insulin with rat adipose cells on the intracellular levels of cyclic AMP. Clin Sci Mol Med 1974 0.75
123 Treatment of Paget's disease of bone with porcine calcitonin. Med J Aust 1974 0.75
124 Androgens in women: source, nature and investigation. Australas J Dermatol 1985 0.75
125 Treatment of hypertension in diabetes. Saudi J Kidney Dis Transpl 2008 0.75
126 Glomerular filtration rate in early experimental diabetes. J Diabet Complications 1988 0.75
127 Coma and thyroid dysfunction. Anaesth Intensive Care 1992 0.75
128 Tachyphylaxis to alpha- and beta-angiotensin in dogs perfused with Ringer's solution or blood. Circ Res 1968 0.75
129 Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia. Med J Aust 1990 0.75
130 Semi-quantitative determination of microalbuminuria by urinary dipstick. Aust N Z J Med 1992 0.75
131 Diabetes and hypertension: prognostic and therapeutic considerations. Blood Press 1995 0.75
132 Effect of glycaemic control on glomerular filtration rate in the streptozotocin diabetic rat. Clin Exp Pharmacol Physiol 1988 0.75
133 Long-term intraindividual variability of serum lipids in patients with type I and type II diabetes. J Diabetes Complications 1998 0.75
134 The effects of sodium loading and deprivation on plasma renin and plasma and urinary aldosterone in hypertension. Clin Sci 1972 0.75
135 Longitudinal evaluation of the renal clearance of glycated albumin in the diabetic rat. Diabetes Res Clin Pract 1990 0.75
136 Blood angiotensinase activity in relation to the breakdown of angiotensin II amide and nonisotopic phenylthiocarbamyl-angiotensin II amide in hypertensive and normotensive patients. Cardiovasc Res 1968 0.75
137 Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study. Diabetes Res Clin Pract 1988 0.75
138 The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis. J Am Geriatr Soc 1990 0.75
139 In vivo assessment of an animal model of diabetic cataract: medical intervention studies. Dev Ophthalmol 1994 0.75
140 Accelerated progression of diabetic nephropathy in the spontaneously hypertensive streptozotocin diabetic rat. Clin Exp Pharmacol Physiol 1986 0.75
141 Two types of insulin receptors mediating opposite effects on cyclic-amp in fat cells of the rat. Horm Metab Res 1974 0.75
142 Anomalous decrease in dextran sulfate clearance in the diabetic rat kidney. Am J Physiol 1998 0.75
143 Prolonged hypercalcemia following acute renal failure. Clin Nephrol 1975 0.75
144 Thiazolidinediones and congestive heart failure--exacerbation or new onset of left ventricular dysfunction? Diabet Med 2004 0.75
145 Intermittent diabetic microalbuminuria: association with blood pressure, glycemic control, and protein intake. J Diabet Complications 1989 0.75